NK cell-based therapeutics for lung cancer

References

• Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32:605–644.
   PubMed Web of Science ®Google Scholar
• Morgensztern D, Campo MJ, Dahlberg SE, et al. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015;10:S1–63.
   PubMed Web of Science ®Google Scholar
• Thai AA, Solomon BJ. Treatment of ALK-positive nonsmall cell lung cancer: recent advances. Curr Opin Oncol. 2018;2:84–91.
   Google Scholar
• Recondo G, Faccinetti F, Olaussen KA, et al. Making the first move in EGFR-driven or ALK-driven NSCLC: first –generation or next generation TKI? Nat Rev Clin Oncol. 2018;15:694–708.
   PubMed Web of Science ®Google Scholar
• Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19:813–824.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348:56–61.
   PubMed Web of Science ®Google Scholar
• Vaupel P, Multhoff G. Accomplices of the hypoxic tumor microenvironment compromising antitumor immunity: adenosine, lactate, acidosis, vascular endothelial growth factor, potassium ions and phosphatidylserine. Front Immunol. 2017;8:1887.
   PubMed Web of Science ®Google Scholar
• Najafi M, Hashemi Goradel N, Farhood B, et al. Macrophage polarity in cancer: A review. J Cell Biochem. 2019;120:2756–2765.
   PubMed Web of Science ®Google Scholar
• Giese M, Hind L, Huttenlocher A. Neutrophil plasticity in the tumor microenvironment. Blood. 2019;133:2159–2167.
   Web of Science ®Google Scholar
• Furset G, Floisand Y, Sioud M. Impaired expression of indoleamine 2, 3-dioxygenase in monocyte-derived dendritic cells in response to Toll-like receptor-7/8 ligands. Immunology. 2008;123:263–271.
   PubMed Web of Science ®Google Scholar
• Sim SH, Ahn YO, Yoon J, et al. Influence of chemotherapy on nitric oxide synthase, indole-amine-2,3-dioxygenase and CD124 expression in granulocytes and monocytes of non-small cell lung cancer. Cancer Sci. 2012;103:155–160.
   PubMed Web of Science ®Google Scholar
• Harden JL, Egilmez NK. Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity. Immunol Invest. 2012;41:738–764.
   PubMed Web of Science ®Google Scholar
• Zhang J, Basher F, Wu JD. NKG2D ligands in tumor immunity: two sides of a coin. Front Immunol. 2015;6:97.
   PubMed Web of Science ®Google Scholar
• Ferlazzo G, Pack M, Thomas D, et al. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. PNAS. 2004;101:16606–16611.
   PubMed Web of Science ®Google Scholar
• Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331:44–49.
   PubMed Web of Science ®Google Scholar
• Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nature Rev Cancer. 2016;16:7–19.
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Cooper MA, Nuovo GJ, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. 2003;101:3052–3057.
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22:633–640.
   PubMed Web of Science ®Google Scholar
• Freud AG, Mundy-Bosse BL, Yu J, et al. The broad spectrum of human natural killer cell diversity. Immunity. 2017;47:820–833.
   PubMed Web of Science ®Google Scholar
• Wagner JA, Rosario M, Romee R, et al. CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. J Clin Invest. 2017;127:4042–4058.
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001;97:14–32.
   PubMed Web of Science ®Google Scholar
• Nagler A, Lanier LL, Phillips JH. Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo. J Exp Med. 1990;171:1527–1533.
   PubMed Web of Science ®Google Scholar
• Borrego F, Masilamani M, Kabat J, et al. The cell biology of the human natural killer cell CD94/NKG2A inhibitory receptor. Mol Immunol. 2005;42:485–488.
   PubMed Web of Science ®Google Scholar
• Vales-Gomez M, Reyburn HT, Erskine RA, et al. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2C to HLA-E. Embo J. 1999;18:4250–4260.
   PubMed Web of Science ®Google Scholar
• Kruse PH, Matta J, Ugolini S, et al. Natural cytotoxicity receptors and their ligands. Immunol Cell Biol. 2014;92:221–229.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wu N, Lu Y, et al. DNAM-1 controls NK cell activation via an ITT-like motif. J Exp Med. 2015;212:2165–2182.
   PubMed Web of Science ®Google Scholar
• Triebel F, Jitsukawa S, Baixeras E, et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med. 1990;171:1393–1405.
   PubMed Web of Science ®Google Scholar
• Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44:989–1004.
   PubMed Web of Science ®Google Scholar
• Baessler T, Charton JE, Schmiedel BJ, et al. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood. 2010;115:3058–3069.
   PubMed Web of Science ®Google Scholar
• Martinet L, Smyth MJ. Balancing natural killer cell activation through paired receptors. Nature Rev Immunol. 2015;15:243–254.
   PubMed Web of Science ®Google Scholar
• Kumar S. Natural killer cell cytotoxicity and its regulation by inhibitory receptors. Immunol. 2018;154:383–393.
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 2001;97:3146–3151.
   PubMed Web of Science ®Google Scholar
• Nakamura S, Kuroki K, Ohki I, et al. Molecular basis for E-cadherin recognition by killer cell lectin-like receptor G1 (KLRG1). J Biol Chem. 2009;284:27327–27335.
   PubMed Web of Science ®Google Scholar
• Elsner L, Flugge PF, Lozano J, et al. The endogenous danger signals HSP70 and MICA cooperate in the activation of cytotoxic effector functions of NK cells. J Cell Mol Med. 2010;14:992–1002.
   PubMed Web of Science ®Google Scholar
• Candeias S, Testard I. The many interactions between the innate immune system and the response to radiation. Cancer Lett. 2015;356:173–178.
   Google Scholar
• Gasser S, Orsulic S, Brown EJ, et al. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005;436:1186–1190.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8:59–73.
   PubMed Web of Science ®Google Scholar
• Martinet L, Ferrari De Andrade L, Guillerey C, et al. DNAM-1 expression marks an alternative program of NK cell maturation. Cell Rep. 2015;11:85–97.
   PubMed Web of Science ®Google Scholar
• de Andrade LF, Smyth MJ, Martinet L. DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins. Immunol Cell Biol. 2014;92:237–244.
   PubMed Web of Science ®Google Scholar
• Borrego F, Ulbrecht M, Weiss EH, et al. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J Exp Med. 1998;187:813–818.
   PubMed Web of Science ®Google Scholar
• Stangl S, Gehrmann M, Riegger J, et al. Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. PNAS. 2011;108:733–738.
   PubMed Web of Science ®Google Scholar
• Multhoff G, Botzler C, Jennen L, et al. Heat shock protein 72 on tumor cells: a recognition structure for natural killer cells. J Immunol. 1997;158:4341–4350.
   PubMed Web of Science ®Google Scholar
• Bradley M, Zeytun A, Rafi-Janajreh A, et al. Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas+ and Fas- tumor cells. Blood. 1998;92:4248–4255.
   PubMed Web of Science ®Google Scholar
• Talanian RV, Yang X, Turbov J, et al. Granule-mediated killing: pathways for granzyme B-initiated apoptosis. J Exp Med. 1997;186:1323–1331.
   PubMed Web of Science ®Google Scholar
• Abel AM, Yang C, Thakar MS, et al. Natural killer cells: development, maturation, and clinical utilization. Front Immunol. 2018;9:1869.
   PubMed Web of Science ®Google Scholar
• Kärre K, Ljunggren HG, Piontek G, et al. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319:675–678.
   PubMed Web of Science ®Google Scholar
• Obeid M, Panaretakis T, Joza N, et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Diff. 2007;14:1848–1850.
   PubMed Web of Science ®Google Scholar
• Multhoff G. Activation of natural killer cells by heat shock protein 70. Int J Hyperthermia. 2002;18:576–585.
   PubMed Web of Science ®Google Scholar
• Luna JI, Grossenbacher SK, Murphy WJ, et al. Targeting cancer stem cells with natural killer cell immunotherapy. Exp Opinion Biol Ther. 2017;17:313–324.
   PubMed Web of Science ®Google Scholar
• Daeron M, Jaeger S, Du Pasquier L, et al. Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future. Immunol Rev. 2008;224:11–43.
   PubMed Web of Science ®Google Scholar
• Andre P, Denis C, Soulas C, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175:1731–43 e13.
   PubMed Web of Science ®Google Scholar
• Nayyar G, Chu Y, Cairo MS. Overcoming resistance to natural killer cell based immunotherapies for solid tumors. Front Oncol. 2019;9:51.
   PubMed Web of Science ®Google Scholar
• Lee N, Llano M, Carretero M, et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. PNAS. 1998;95:5199–5204.
   PubMed Web of Science ®Google Scholar
• Hodge G, Barnawi J, Jurisevic C, et al. Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-gamma by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells. Clin Exp Immunol. 2014;178:79–85.
   PubMed Web of Science ®Google Scholar
• Jinushi M, Takehara T, Tatsumi T, et al. Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas. J Hepatol. 2005;43:1013–1020.
   PubMed Web of Science ®Google Scholar
• Huang AL, Liu SG, Qi WJ, et al. TGF-beta1 protein expression in non-small cell lung cancers is correlated with prognosis. Asian Pacific J Cancer Prev. 2014;15:8143–8147.
   PubMed Web of Science ®Google Scholar
• De Vita F, Orditura M, Galizia G, et al. Serum interleukin-10 is an independent prognostic factor in advanced solid tumors. Oncol Rep. 2000;7:357–361.
   PubMed Web of Science ®Google Scholar
• Cummins EP, Oliver KM, Lenihan CR, et al. NF-kappaB links CO2 sensing to innate immunity and inflammation in mammalian cells. J Immunol. 2010;185:4439–4445.
   PubMed Web of Science ®Google Scholar
• Park KG, Hayes PD, Garlick PJ, et al. Stimulation of lymphocyte natural cytotoxicity by L-arginine. Lancet. 1991;337:645–646.
   PubMed Web of Science ®Google Scholar
• Witz IP. Tumor-microenvironment interactions: the selectin-selectin ligand axis in tumor-endothelium cross talk. Cancer Treat Res. 2006;130:125–140.
   PubMedGoogle Scholar
• Ghiringhelli F, Menard C, Martin F, et al. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunological Rev. 2006;214:229–238.
   PubMed Web of Science ®Google Scholar
• Vaupel P, Multhoff G. Fatal alliance of hypoxia-/HIF-1α-driven microenvironmental traits promoting cancer progression and resistance to therapy. Adv Exp Med Biol. 2019. In press.
   Google Scholar
• Zilio S, Serafini P. Neutrophils and granulocytic MDSC: the janus god of cancer immunotherapy. Vaccines (Basel). 2016;4:E31.
   PubMed Web of Science ®Google Scholar
• Domagala-Kulawik J, Osinska I, Hoser G. Mechanisms of immune response regulation in lung cancer. Transl Lung Cancer Res. 2014;3:15–22.
   PubMedGoogle Scholar
• Petersen RP, Campa MJ, Sperlazza J, et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 2006;107:2866–2872.
   PubMed Web of Science ®Google Scholar
• Shigematsu Y, Hanagiri T, Shiota H, et al. Immunosuppressive effect of regulatory T lymphocytes in lung cancer, with special reference to their effects on the induction of autologous tumor-specific cytotoxic T lymphocytes. Oncol Lett. 2012;4:625–630.
   PubMed Web of Science ®Google Scholar
• Stangl S, Tontcheva N, Sievert W, et al. Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German cancer consortium radiation oncology group (DKTK-ROG). Int J Cancer. 2018;142:1911–1925.
   PubMed Web of Science ®Google Scholar
• Hatanaka H, Abe Y, Kamiya T, et al. Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Annals Oncol. 2000;11:815–819.
   PubMed Web of Science ®Google Scholar
• Srivastava MK, Zhu L, Harris-White M, et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PloS One. 2012;7:e40677.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Sozzani S, Locati M, et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549–555.
   PubMed Web of Science ®Google Scholar
• Barlesi F, Vansteenkiste J, Spigel D, et al. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200: an open-label, randomised, phase 3 study. Lancet Oncol. 2018;11:1468–1479.
   Google Scholar
• Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819–1830.
   PubMed Web of Science ®Google Scholar
• Network NCC. Non-small cell lung cancer (Version 3.2019). cited 2019 Feb 6]. Available from: https://wwwnccnorg/professionals/physican_gls/pdf/nsclpdf
   Google Scholar
• Langer CJ. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. American J Clin Oncol. 2015;38:422–430.
   PubMed Web of Science ®Google Scholar
• Pacheco JM, Camidge DR, Doebele RC, et al. A changing of the guard: immune checkpoint inhibitors with and without chemotherapy as first line treatment for metastatic non-small cell lung cancer. Front Oncol. 2019;9:195.
   PubMed Web of Science ®Google Scholar
• Reck M, Borghaei H, O’Byrne KJ. Nivolumab plus ipilimumab in non-small-cell lung cancer. Future Oncol. 2019. In press.
   Google Scholar
• Addeo A, Banna GL, Metro G, et al. Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: a systematic review and literature-based meta-analysis. Front Oncol. 2019;9:264.
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S, Horn LA, Haile ST. The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J Immunol. 2014;193:3835–3841.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Smyth MJ, et al. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity. 2013;39:74–88.
   PubMed Web of Science ®Google Scholar
• Pesce S, Greppi M, Grossi F, et al. PD/1-PD-Ls checkpoint: insight on the potential role of NK cells. Front Immunol. 2019;10:1242.
   PubMed Web of Science ®Google Scholar
• Domagala-Kulawik J. Immune checkpoint inhibitors in non-small cell lung cancer - towards daily practice. Adv Respir Med. 2018;86(3).
   Web of Science ®Google Scholar
• Rosenberg SA, Eberlein TJ, Grimm EA, et al. Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer. Surgery. 1982;92:328–336.
   PubMed Web of Science ®Google Scholar
• Wu Y, Tian Z, Wei H. Developmental and functional control of natural killer cells by cytokines. Front Immunol. 2017;8:930.
   PubMed Web of Science ®Google Scholar
• Kim S, Iizuka K, Aguila HL, et al. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. PNAS. 2000;97:2731–2736.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Nat Cancer Inst. 1993;85:622–632.
   PubMed Web of Science ®Google Scholar
• Vitale M, Cantoni C, Pietra G, et al. Effect of tumor cells and tumor microenvironment on NK-cell function. Europ J Immunol. 2014;44:1582–1592.
   PubMed Web of Science ®Google Scholar
• Zhang G, Zhao H, Wu J, et al. Adoptive immunotherapy for non-small cell lung cancer by NK and cytotoxic T lymphocytes mixed effector cells: retrospective clinical observation. Int Immunopharmacol. 2014;21:396–405.
   PubMed Web of Science ®Google Scholar
• Lin M, Liang SZ, Shi J, et al. Circulating tumor cell as a biomarker for evaluating allogenic NK cell immunotherapy on stage IV non-small cell lung cancer. Immunol Lett. 2017;191:10–15.
   PubMed Web of Science ®Google Scholar
• Iliopoulou EG, Kountourakis P, Karamouzis MV, et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother. 2010;59:1781–1789.
   PubMed Web of Science ®Google Scholar
• Multhoff G, Pfister K, Gehrmann M, et al. A 14-mer Hsp70 peptide stimulates natural killer (NK) cell activity. Cell Stress Chaperones. 2001;6:337–344.
   PubMed Web of Science ®Google Scholar
• Gehrmann M, Pfister K, Hutzler P, et al. Effects of antineoplastic agents on cytoplasmic and membrane-bound heat shock protein 70 (Hsp70) levels. Biol Chem. 2002;383:1715–1725.
   PubMed Web of Science ®Google Scholar
• Stangl S, Themelis G, Friedrich L, et al. Detection of irradiation-induced, membrane heat shock protein 70 (Hsp70) in mouse tumors using Hsp70 Fab fragment. Radiother Oncol. 2011;99:313–316.
   PubMed Web of Science ®Google Scholar
• Multhoff G. Heat shock protein 72 (HSP72), a hyperthermia-inducible immunogenic determinant on leukemic K562 and Ewing’s sarcoma cells. Int J Hyperthermia. 1997;13:39–48.
   PubMed Web of Science ®Google Scholar
• Krause SW, Gastpar R, Andreesen R, et al. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial. Clin Cancer Res. 2004;10:3699–3707.
   PubMed Web of Science ®Google Scholar
• Shevtsov M, Pitkin E, Ischenko A, et al. Ex vivo Hsp70-activated NK cells in combination with PD-1 inhibition significantly increase overall survival in preclinical models of glioblastoma and lung cancer. Front Immunol. 2019;10:454.
   PubMed Web of Science ®Google Scholar
• Specht HM, Ahrens N, Blankenstein C, et al. Heat shock protein 70 (Hsp70) peptide activated natural killer (NK) cells for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCTx) - from preclinical studies to a clinical phase II trial. Front Immunol. 2015;6:162.
   PubMed Web of Science ®Google Scholar
• Kokowski K, Stangl S, Seier S, et al. Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study. Strahlenther Onkol. 2019;195:352–361.
   PubMed Web of Science ®Google Scholar
• Ding X, Cao H, Chen X, et al. Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer. J Translational Med. 2015;13:158.
   PubMed Web of Science ®Google Scholar
• Aktas ON, Ozturk AB, Erman B, et al. Role of natural killer cells in lung cancer. J Can Res Clin Oncol. 2018;144:997–1003.
   PubMed Web of Science ®Google Scholar
• Miller JS, Morishima C, McNeel DG, et al. A first-in-human phase I study of subcutaneous outpatient recombinant human IL15 (rhIL15) in adults with advanced solid tumors. Clin Cancer Res. 2018;24:1525–1535.
   PubMed Web of Science ®Google Scholar
• Han KP, Zhu X, Liu B, et al. IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine. 2011;56:804–810.
   PubMed Web of Science ®Google Scholar
• Wrangle JM, Velcheti V, Patel MR, et al. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase Ib trial. Lancet Oncol. 2018;19:694–704.
   PubMed Web of Science ®Google Scholar
• Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497.
   PubMed Web of Science ®Google Scholar
• Park S, Jiang Z, Mortenson ED, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell. 2010;18:160–170.
   PubMed Web of Science ®Google Scholar
• Abes R, Dutertre CA, Agnelli L, et al. Activating and inhibitory Fcgamma receptors in immunotherapy: being the actor or being the target. Expert Rev Clin Immunol. 2009;5:735–747.
   PubMed Web of Science ®Google Scholar
• Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol. 2003;171:1581–1587.
   PubMed Web of Science ®Google Scholar
• Anegon I, Cuturi MC, Trinchieri G, et al. Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. J Exp Med. 1988;167:452–472.
   PubMed Web of Science ®Google Scholar
• Boutet P, Aguera-Gonzalez S, Atkinson S, et al. Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol. 2009;182:49–53.
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Houot R, Weiskopf K, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest. 2012;122:1066–1075.
   PubMed Web of Science ®Google Scholar
• Fernerty KE, Pdget M, Wolfson B, et al. Immunotherpy utilizing the combination of natural killer-and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) plymerase (PARP) inhibition. J Immunother Cancer. 2018;6:133.
   PubMed Web of Science ®Google Scholar
• Eissler N, Ruf P, Mysliwietz J, et al. Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect. Cancer Res. 2012;72:3958–3966.
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Hayakawa Y, Takeda K, et al. New aspects of natural-killer-cell surveillance and therapy of cancer. Nature Rev Cancer. 2002;2:850–861.
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321:974–977.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Eng J Med. 2012;366:2443–2454.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New Eng J Med. 2012;366:2455–2465.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Diab A, Perales MA, et al. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. Cancer Res. 2006;66:4904–4912.
   PubMed Web of Science ®Google Scholar
• Tonn T, Schwabe D, Klingemann HG, et al. Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy. 2013;15:1563–1570.
   PubMed Web of Science ®Google Scholar
• Sahm C, Schonfeld K, Wels WS. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunol Immunother. 2012;61:1451–1461.
   PubMed Web of Science ®Google Scholar
• Veluchamy JP, Kok N, Van der Fleet HJ, et al. The rise of allogeneic natural killer cells as a platform for cancer immuno therapy: recent innovations an future developments. Front Immunol. 2017;8:631.
   PubMed Web of Science ®Google Scholar
• Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051–3057.
   PubMed Web of Science ®Google Scholar
• Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102:814–819.
   PubMed Web of Science ®Google Scholar
• Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res. 2001;83:117–158.
   PubMed Web of Science ®Google Scholar
• Ramnath N, Tan D, Li Q, et al. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunol Immunother. 2006;55:891–899.
   PubMed Web of Science ®Google Scholar
• He Y, Liu S, Mattei J, et al. The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC. Drug Des Devel Ther. 2018;12:981–986.
   PubMed Web of Science ®Google Scholar
• Koehl U, Kalberer C, Spanholtz J, et al. Advances in clinical NK cell studies: donor selection, manufacturing and quality control. Oncoimmunol. 2016;5:e1115178.
   PubMed Web of Science ®Google Scholar
• Baggio L, Laureano AM, Silla L, et al. Natural killer cell adoptive immunotherapy: coming of age. Clin Immunol. 2017;177:3–11.
   PubMed Web of Science ®Google Scholar
• Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev. 2006;20:123–137.
   PubMed Web of Science ®Google Scholar
• Glienke W, Esser R, Priesner C, et al. Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol. 2015;6:21.
   PubMed Web of Science ®Google Scholar
• Boissel L, Betancur-Boissel M, Lu W, et al. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunol. 2013;2:e26527.
   PubMed Web of Science ®Google Scholar
• Handgretinger R, Anderson K, Lang P, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Europ J Cancer. 1995;31A:261–267.
   PubMed Web of Science ®Google Scholar
• Chen X, Han J, Chu J, et al. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget. 2016;7:27764–27777.
   PubMedGoogle Scholar
• Tassev DV, Cheng M, Cheung NK. Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor. Cancer Gene Ther. 2012;19:84–100.
   PubMed Web of Science ®Google Scholar
• Altvater B, Landmeier S, Pscherer S, et al. 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res. 2009;15:4857–4866.
   PubMed Web of Science ®Google Scholar
• Kruschinski A, Moosmann A, Poschke I, et al. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. PNAS. 2008;105:17481–17486.
   PubMed Web of Science ®Google Scholar
• Shimasaki N, Fujisaki H, Cho D, et al. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy. 2012;14:830–840.
   PubMed Web of Science ®Google Scholar
• Handgretinger R, Lang P, Andre MC. Exploitation of natural killer cells for the treatment of acute leukemia. Blood. 2016;127:3341–3349.
   PubMed Web of Science ®Google Scholar
• Cany J, van der Waart AB, Tordoir M, et al. Natural killer cells generated from cord blood hematopoietic progenitor cells efficiently target bone marrow-residing human leukemia cells in NOD/SCID/IL2Rg(null) mice. PloS One. 2013;8:e64384.
   PubMed Web of Science ®Google Scholar
• Ramos CA, Heslop HE, Brenner MK. CAR-T Cell Therapy for Lymphoma. Annual Rev Med. 2016;67:165–183.
   PubMed Web of Science ®Google Scholar
• Vey N, Karlin L, Sadot-Lebouvier S, et al. A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies. Oncotarget. 2018;9:17675–17688.
   PubMedGoogle Scholar
• Geng JJ, Tang J, Yang XM, et al. Targeting CD147 for T to NK Lineage Reprogramming and Tumor Therapy. E Bio Medicine. 2017;20:98–108.
   Google Scholar
• Zhang J, Liu D, Li G, et al. Antibody-mediated neutralization of soluble MIC significantly enhances CTLA-4 blockade therapy. Science Adv. 2017;3:e1602133.
   PubMed Web of Science ®Google Scholar
• Gruel N, Fridman WH, Teillaud JL. Bypassing tumor-specific and bispecific antibodies: triggering of antitumor immunity by expression of anti-FcgammaR scFv on cancer cell surface. Gene Ther. 2001;8:1721–1728.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. New Eng J Med. 2016;375:1823–1833.
   PubMed Web of Science ®Google Scholar
• Lopes G, Wu Y-W, Kudaba I, et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: open-label phase 3 KEYNOTE-042 study. J Clin Oncol. 2018;36:18.
   Google Scholar
• Administration USFaD; 2019. [cited 2019 Jan 29]. Available from: www.FDA.gov.
   Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. New Eng J Med. 2017;377:1919–1929.
   PubMed Web of Science ®Google Scholar